Janssen Pharmaceutica NV has identified bicyclic pyridin-2-one and pyrimidin-4-one derivatives acting as coagulation factor XIa inhibitors and thus reported to be useful for the treatment of thromboembolism, diabetes, diabetic retinopathy, septic shock, hereditary angioedema, arthritis, nephropathy and inflammatory disorders, among others.

Gluetacs Therapeutics (Shanghai) Co. Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a target protein binding moiety through a linker.

Researchers at Shanghai Institute of Materia Medica and the Wuhan Institute of Virology Chinese Academy of Sciences have prepared and tested cyclic bisbenzyl tetrahydroisoquinoline compounds reported to be useful for the treatment of fibrosis, viral infections and inflammatory disorders.

Daegu-Gyeongbuk Medical Innovation Foundation and Seoul National University Hospital have jointly developed adiponectin-derived peptoid derivatives reported to be useful for the treatment of skin inflammation, wound infection, alopecia, fibrosis, aging, skin wrinkling, cancer and metabolic diseases, among others.

Recent Deciphera Pharmaceuticals LLC patents describe Raf kinase B and/or C inhibitors reported to be useful for the treatment of cancer.

A Pfizer Inc. patent describes new melanocortin MC4 receptor antagonists reported to be useful for the treatment of cachexia, anorexia and anorexia nervosa.

Pretzel Therapeutics Inc. has patented heterocycle-containing compounds acting as Lon protease homolog, mitochondrial (LONP1) inhibitors. They are reported to be useful for the treatment of cancer, aging, neurodegeneration and metabolic diseases.

Prothena Biosciences Ltd. has developed dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of Alzheimer’s disease.

Research at Betta Pharmaceuticals Co. Ltd. has led to the identification of new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shionogi & Co. Ltd. has reported aromatic heterocyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists and reported to be useful for the treatment of obesity and type 2 diabetes.